• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Abpro Holdings Inc

    4/1/25 8:40:12 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABP alert in real time by email
    NT 10-K 1 ea0236444-nt10k_abprohold.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

    Commission File Number: 001-41224

     

    For Period Ended: December 31, 2024

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

    ☐ Transition Report on Form N-SAR

    For the Transaction Period Ended: __________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Abpro Holdings, Inc.

    Full Name of Registrant

     

    Atlantic Coastal Acquisition Corp. II

    Former Name if Applicable

     

    68 Cummings Park Drive

    Address of Principal Executive Office (Street and Number)

     

    Woburn, Massachusetts 01801

    City, State and Zip Code

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a)     The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b)    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
      (c)     The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Abpro Holdings, Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”) by the prescribed due date because the Company is in the process of preparing the financial statements for the year ended December 31, 2024 and will need additional time to complete such financial statements. The Company anticipates that it will file its Form 10-K within the fifteen-day extension period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    PART IV — OTHER INFORMATION

     

    (1)Name and telephone number of person to contact in regard to this notification

     

    Miles Suk   1-800   396-5890
    (Name)   (Area Code)   (Telephone Number)

     

    (2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    ☒ Yes ☐ No

     

    (3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐ Yes ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    2

     

     

    Abpro Holdings, Inc.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 1, 2025 By: /s/ Miles Suk
         

    Name:

    Miles Suk

          Title: Chief Executive Officer

     

    3

     

    Get the next $ABP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

    FDA clearance enables initiation of Abpro's first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, Abpro's lead multispecific antibody oncology program. The IND clearance enables the

    1/6/26 7:00:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

     IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP, "Abpro")), a biotechnology company developing novel breakthrough therapeutics for solid tumors, together with its co-development partner Celltrion, Inc., today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA

    12/15/25 7:00:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

    BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro" or the "Company"), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements. "We view this extension as a recognition that our compliance plan merits continued evaluation as we work to stabilize our business and build lasting momentum," said Miles Suk, Chief Executive Officer and Chairman of Abpro. "We've taken decisive steps to position the Company for sustainable growth. With

    12/9/25 7:00:00 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Suk Jin Wook (Miles) bought $20,170 worth of shares (72,035 units at $0.28), increasing direct ownership by 11% to 718,512 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/4/25 5:22:41 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    5/19/25 8:37:52 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    5/1/25 4:21:30 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lee Soo Young

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/7/25 9:08:24 AM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Suk Jin Wook (Miles) bought $20,170 worth of shares (72,035 units at $0.28), increasing direct ownership by 11% to 718,512 units (SEC Form 4)

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    8/4/25 5:22:41 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Eisenberg Anthony D.

    4 - Abpro Holdings, Inc. (0001893219) (Issuer)

    7/29/25 9:23:12 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    SEC Filings

    View All

    Abpro Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8-K - Abpro Holdings, Inc. (0001893219) (Filer)

    2/11/26 4:15:54 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Abpro Holdings Inc

    SCHEDULE 13G - Abpro Holdings, Inc. (0001893219) (Subject)

    2/9/26 4:07:42 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abpro Holdings Inc filed SEC Form 8-K: Leadership Update

    8-K - Abpro Holdings, Inc. (0001893219) (Filer)

    2/3/26 4:15:45 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABP
    Leadership Updates

    Live Leadership Updates

    View All

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Abpro Statement on the Departure of Former CEO Ian Chan

    WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

    3/10/25 6:34:55 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care